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Aspirin-Exacerbated Asthma
Mathew Varghese, MD and Richard F. Lockey, MD
This review focuses on aspirin-exacerbated asthma (AEA). The review includes historical perspective of aspirin, prevalence,
pathogenesis, clinical features and treatment of AEA. The pathogenesis of AEA involves the cyclooxygenase and lipooxygenase
pathway. Aspirin affects both of these pathways by inhibiting the enzyme cycooxygenase-1 (COX-1). Inhibition of COX-1 leads to a
decrease in prostaglandin E2 (PGE2). The decrease in PGE2 results in an increase in cysteinyl leukotrienes by the lipooxygenase
pathway involving the enzyme 5-lipooxygenase (5-LO). Leukotriene C4 (LTC4) synthase is the enzyme responsible for the production
of leukotriene C4, the chief cysteinyl leukotriene responsible for AEA. There have been familial occurences of AEA. An allele of the
LTC4 synthase gene in AEA is known as allele C. Allele C has a higher frequency in AEA. Clinical presentation includes a history of
asthma after ingestion of aspirin, nasal congestion, watery rhinorrhea and nasal polyposis. Treatment includes leukotriene receptor
antagonists, leukotriene inhibitors, aspirin desinsitaztion and surgery. AEA is the most well-defined phenotype of asthma. Although
AEA affects adults and children with physician-diagnosed asthma, in some cases there is no history of asthma and AEA often goes
unrecognized and underdiagnosed.
Key words: aspirin desensitization, aspirin exacerbated asthma, aspirin exacerbated respiratory disease, aspirin sensitive asthma,
cysteinyl leukotriene, leukotriene, leukotriene C4, leukotriene C4 synthase
A
cetylsalicylic acid (aspirin) is one of the most
prescribed and frequently used over-the-counter
medications of all time. Aspirin-exacerbated asthma
(AEA) was first reported 84 years ago after severe
bronchospasm in an individual with asthma was observed
following aspirin ingestion and is characterized by
eosinophilic rhinosinusitis, nasal polyposis, aspirin sensi-
tivity, and asthma.
1,2 All cyclooxygenase-1 (COX-1)
inhibiting nonsteroidal anti-inflammatory drugs
(NSAIDs), including aspirin, induce bronchospasm, rhi-
norrhea, and nasal obstruction in these subjects.
2–4 In
addition, the ocular administration of the COX-1-inhibit-
ing NSAID ketorolac has been linked to AEA.
4 Individuals
with AEA usually have moderate to severe persistent
asthma and often require treatment with high-dose inhaled
corticosteroids and even systemic corticosteroids in some
instances.
2,5 Although the exact mechanism causing the
AEA has yet to be fully elucidated, there is considerable
evidence that an alteration in the metabolism of arachi-
donic acid is responsible.
5–8
Another clinical entity, chronic idiopathic urticaria
with aspirin sensitivity, although perhaps similar at a
biochemical level to AEA, is clinically different as this
reaction is confined to the skin and subcutaneous tissues.
9
This review focuses on AEA.
Historical Perspective and Background
The medicinal properties of the group of alkali metal salts
and esters known as salicylates have been known since
ancient times. Records dating back to the time of
Hippocrates (460 BC) describe powders derived from the
bark of the white willow tree (Salix alba) used for pain
relief; the name salicylic acid is derived from Salix, the
Latin name for this tree.
10–13 In 1853, the French chemist
Gerhardt neutralized salicylic acid by buffering it with
sodium salicylate and acetylchloride, creating acetylsa-
licylic acid or aspirin. The discovery of aspirin by Gerhardt
was abandoned until Felix Hoffman, a German chemist,
rediscovered it in 1887 and learned of its unique property
of reduced gastrointestinal irritation compared with
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Bayer in 1889 as a new analgesic wonder drug. The
reduced gastrointestinal irritation can be attributed to the
acetylation of the phenolic hydroxyl group (-OH) of
sodium acetylate.
14
Salicylic acid was synthesized by Kolbe, a German
chemist, in 1874 and was used as a analgesic; however,
severe gastrointestinal irritation was a common side effect.
In 1876, MacLagan and Stricker demonstrated that
salicylic acid was an effective treatment for rheumatic
fever; it was used later for chronic rheumatoid arthritis and
gout.
15
Today salicylic acid and its derivatives have a variety of
clinical uses. Salicylic acid is often used because of its
keratinolytic properties as a topical solution for acne,
cutaneous exfoliation in chemical skin peels, and psoriasis
and for treatment of cutaneous fungal infections.
16 Aspirin
is used as an analgesic and to treat fever, migraine,
rheumatic fever (drug of choice), Kawasaki disease (along
with intravenous immunoglobulin), pericarditis, and even
ulcerative colitis (5-acetylsalicylic acid or mesalamine).
17
In addition, it is used to prevent coronary artery disease
and for both primary and secondary prevention of
cerebrovascular accidents.
18
However, serious side effects are associated with its use,
such as occurs in AEA. There are both short- and long-
term side effects of aspirin, such as nephropathy, gastritis,
peptic ulcer disease, prolonged bleeding, and Reye
syndrome.
19,20 AEA was first described by Widal and
colleagues in 1922. In 1967, Samter and Beers reported and
popularized the phenomenon of AEA (Table 1).
21
Definition
Over the past several decades, AEA has also been referred
to as the Samter triad, aspirin triad, aspirin-sensitive
asthma, aspirin-intolerant asthma (ATA), aspirin sensitiv-
ity, and aspirin-exacerbated respiratory disease. AEA best
defines this phenomenon as this term describes the disease
in which the exacerbation of asthma occurs following the
ingestion of aspirin and other COX-1 inhibiting NSAIDs.




Jenkins and colleagues found that prevalence rates are 21%
and 5% for asthmatic adults and children, respectively,
when examining primarily unblinded oral provocation
tests in a systematic review of 66 articles on AEA.
24
Prevalence was dependent on the method used to diagnose
AEA, with patients’ histories alone giving a much lower
prevalence rate of 2.7% in adults and 2% in children. In
1967, Vanselow first reported AEA exacerbated by
indomethacin.
3 Jenkins and colleagues confirmed the
finding that some other NSAIDs also exacerbated AEA
by reporting the sensitivity to ibuprofen, , 400 mg, of
98%; naproxen, 100 mg, of 100%; and diclofenac , 40 mg,
of 76 to 100%.
24 Vally and colleagues reported that the
prevalence of respiratory symptoms triggered by aspirin in
three different asthma study populations surveyed in
Australia was 10 to 11%.
25 In a random sample by postal
Table 1. Historical Perspective of Aspirin and Aspirin-
Exacerbated Asthma
Date Person Discovery
460 BC Hippocrates Described properties of
powders derived from bark
of white willow tree (Salix
alba)
1853 Gerhardt Created ASA by acetylation of
phenolic hydroxyl group of
salicylic acid
1874 Kolbe Synthesis of salicylic acid, used
as a painkiller, although
with severe GI side effects
1889 Hoffman Rediscovered the medicinal
properties of ASA without
GI irritation; mass
marketing by Bayer
1922 Abrami and Lemoyez Reported a case of anaphylaxis
to 100 mg ASA
1967 Samter and Beers Reported the phenomena of
ASA intolerance, nasal
polyposis, asthma
1967 Vanselow Bronchial asthma induced by
indomethacin
1971 Sir John Vane Identified mechanism of
action of ASA as inhibition
of cyclooxygenase pathway
1973 Lockey et al Reported mechanism of the
mode of inheritance of AEA
as autosomal recessive
1980 Stevenson Reported successful
desensitization to ASA
1994 Szczeklik Reported eicosanoids
(cysteinyl leukotrienes) in
pathogenesis of AEA
AEA 5 aspirin-exacerbated asthma; ASA 5 acetylsalicylic acid; GI 5
gastrointestinal.
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of AEA reported in the general population was 1.2%;
however, individuals with pre-existing physician-diag-
nosed asthma had reported prevalence rates of 8.8%.
26 A
database study from Poland in which 12,971 adults were
randomly selected showed a prevalence of AEA of 0.6% in
the general population and 4.3% of subjects with a known
diagnosis of asthma.
27 With nasal polyps, aspirin sensi-
t i v i t ym a yb ea sh i g ha s1 4t o2 2 % ,a n dw i t hc h r o n i c
rhinitis, it is 0.7 to 2.6%.
28 AEA may be widely
underdiagnosed; for example, in the European Network
of Aspirin-Induced Asthma (AIANE), 18% of participants
were unaware of aspirin sensitivity before undergoing
unblinded aspirin provocation tests. The reasons for
underdiagnosis may be the lack of recognition by the AEA
individual of mild symptoms induced by aspirin and low
clinical awareness of this syndrome among health care
professionals.
29 A study by Lockey and colleagues showed
that if subjects are not double-blind challenged, the results
m a yb ef a l s e l yp o s i t i v e .O n l yo n eo ft h r e eo ft h e
individuals challenged had positive results when tested
using double-blind, controlled challenges. Therefore,
without double-blinded challenges, the true prevalence
of AEA cannot be ensured.
30
Pathogenesis
An immunoglobulin E (IgE) mechanism does not explain
the AEA phenomena. An elevated total IgE, dermograph-
ism, and increased sensitivity to antibiotics were associated
with AEA in one study, but skin test responses with lysine-
aspirin were negative. No antibodies against aspirin or
other NSAIDs have been consistently detected in this
disease.
2,31–35
In 1971, Vane added credence to the theory that
aspirin-precipitated attacks are not due to an allergic
reaction but to inhibition of COX-1 in the airways when
he discovered that aspirin inhibited the COX-1 enzyme.
36–41
That discovery led to the AEA COX pathway theory.
Some studies demonstrated an increase in the number
of bronchial submucosal mast cells in AEA compared with
ATA, whereas others have not confirmed this finding.
42,43
The cytokine profile of the mast cell was investigated in
another study and reported an increase in bronchial
submucosal mast cells expressing interleukin-5 and
granulocyte-macrophage colony-stimulating factor.
44
Cowburn and colleagues did not report any significant
differences in bronchial mucosal mast after lysine-aspirin
challenges between ATA and AEA individuals even though
the number of mast cells was lower in both groups when
compared with healthy controls.
45
Cyclooxygenase Pathway
Phospholipids are a class of lipids formed from four
components: a fatty acid, a negatively charged phosphate
group, nitrogen-containing alcohol, and a backbone of
either glycerol or sphingosine. Four different groups of
phospholipases exist, A, B, C, and D, with each group
serving a unique function. Phospholipase A2 produces
arachidonic acid. It is from arachidonic acid that various
eicosanoids are produced from the action of lipoxygenase
and cycloxygenase, namely leukotrienes and prostanoids.
There are two main COX enzymes, COX-1 and COX-2,
encoded by two specific genes on chromosomes 9q32 and
1q25, respectively. COX-3 also exists, and two smaller
forms of COX-1, derived from alternative splicing of
COX-1 messenger ribonucleic acid (mRNA), have been
identified.
46 COX-2 is activated during periods of
inflammation, whereas COX-1 is active during periods of
quiescence.
The inhibition of COX-1 by aspirin causes the
reactions associated with AEA, and this inhibition leads
to a decrease in the production of prostaglandin E2
(PGE2), which acts like a brake on the uncontrolled
synthesis of cysteinyl leukotrienes (Cys-LTs).
47–53 Picado
and colleagues found decreased COX-2 mRNA expression
by analysis of nasal polyps in subjects suffering from
AEA.
48 Since COX-2 was found to be underexpressed,
inadequate COX-2 regulation may also be involved in the
pathogenesis of AEA.
NSAIDs that are highly selective for COX-2, for
example, celecoxib and rofecoxib, do not cause acute
exacerbations of asthma in AEA.
54,55 Cowburn and
colleagues demonstrated that although aspirin removes
PGE2-dependent suppression in all subjects, only in AEA is
there an increase in leukotriene C4 (LTC4) synthase,
leading to a marked overproduction of Cys-LTs.
45
Lipoxygenase Pathway and Production of Cys-LTs
Arachidonic acid is first converted by 5-lipoxygenase (5-
LO) into 5-hydroperoxyeicosatetraenoic acid (5-HPETE)
and then into leukotriene A4 (LTA4). LTA4 is converted
into leukotriene B4 (LTB4) by the enzyme LTA4 epoxide
hydrolase. Eosinophils, mast cells, and alveolar macro-
p h a g e su s et h ee n z y m eL T C 4 synthase to conjugate
glutathione with LTA4 to make LTC4. LTC4 can be
transported out of the cell and its glutamic acid moiety
Aspirin-Exacerbated Asthma 77removed by ubiquitous enzymes to make leukotriene D4
(LTD4). LTD4, in turn, can be cleaved by dipeptidases to
make leukotriene E4 (LTE4). LTC4, LTD4, and LTE4 make
up the Cys-LTs. The Cys-LTs cause bronchoconstric-
tion, mucus plugging and edema, and cellular infiltration
and recruitment in the airways. The overexpression of
Cys-LTs occurs in both bronchial and nasal mucosa in
AEA.
47–53
In a study by Adamjee and colleagues, eosinophils from
nasal polyps, immunopositive for LTC4 synthase, were
fourfold more numerous in AEA than in ATA. There were
also threefold more cells expressing 5-LO in the nasal
polyp mucosa. These investigators found that fivefold
higher eosinophil counts accounted for the increased LTC4
synthase expression in polyps from AEA.
53
The inhibitory effect of PGE2 in AEA was also
investigated in a study that showed that inhaled PGE2
affords almost complete protection in AEA by blocking
aspirin-induced bronchoconstriction. The inhibitory
effect, however, is still controversial as PGE2 levels have
been found to be both increased and decreased in nasal
and bronchial lavages (Figure 1).
52,56,57
Familial Inheritance
Lockey and colleagues in 1973 described four members of
a Mennonite family with AEA, three of whom were first
cousins.
58 One of the cousins, whose husband was a
member of the isolate, had twin daughters, one with AEA
and another with allergic rhinitis and extrinsic asthma but
n oA E A .T h et w i nw i t hA E Aa n dh e rh u s b a n ds h a r e d
common ancestors in the eighth ancestral generation.
The presence of AEA in relatives, influenced by the
presence of consanguinity, suggests an autosomal reces-
sive mode of inheritance. It also suggests that the
d i s c o r d a n c es e e ni nt h et w i n sm a yb ea ni n d i c a t i o no f
environmental influences on the phenotypic expression
of this phenomenon.
58 Also mentioned in this article was
ar e p o r to ft w os i s t e r so fan o n - M e n n o n i t ef a m i l yw h o
had AEA and a third sibling with intrinsic asthma who
improved after aspirin ingestion. Curiously, there are
other case reports of AEA improving after aspirin
ingestion.
30
Miller described a pair of sisters with the AEA in
another report of familial inheritance.
59 Von Maur and
colleagues described a family with mild AEA and suggested
a dominant mode of inheritance.
60 In this study, an early
onset of asthma in most affected members of the family
and a lack of symptoms of sinusitis or nasal polyposis
predominated.
Familial occurrence of AEA was reported in 5.1% of
400 subjects studied in AIANE.
29 In these families, affected
individuals were usually siblings. Szczeklik and Sanak
reported on two sisters, aged 20 and 27 years, who, after
being given unblinded aspirin challenges, had widely
different reactions, with the older sibling experiencing an
asthma exacerbation and the younger marked nasal
congestion.
61 Both sisters shared the variant allele of
LTC4 synthase associated with AEA. The parents of the
twins and some other family members who were atopic or
had moderate eosinophilia were challenged with aspirin
and had negative responses.
LTC4 Synthase
LTC4, one of the Cys-LTs, is proposed as the primary
leukotriene that causes bronchospasm in AEA.
48 Cys-LTs
are first synthesized by 5-LO and 5-lipoxygenase-
associated protein (FLAP 5). Expression of 5-LO is
modulated by a genetic variation in the transcription
factor binding motif of the 5-LO gene. No association
between the allelic variants of 5-LO gene promoter and
AEA has been observed, nor has there been any difference
in the results from immunostaining of bronchial biopsy
specimens for 5-LO and FLAP 5.
53,62
LTC4 synthase is a terminal enzyme that mediates
production of Cys-LTs.
45,53,63 This enzyme is expressed in
eosinophils, basophils, and macrophages. In these cells
LTC4 synthase alternatively converts LTC4 from LTA4.
LTC4 is rendered powerless owing to the lack of
Figure 1. Cox-1 5 cyclooxygenase-1; Cys-LT 5 cysteinyl leukotriene;
LTC4 5 leukotriene C4; LTD4 5 leukotreine D4; LTE4 5 leukotriene
E4; PGE-2 5 prostaglandin E2.
78 Allergy, Asthma, and Clinical Immunology, Volume 4, Number 2, 2008concomitant 5-LO expression in platelets and epithelial
and endothelial cells. Production of LTC4 synthase
depends on external sources of LTA4.
LTC4 synthase has been cloned by Lam and col-
leagues
68 and its function and sequence studied. An allelic
variant of the LTC4 synthase gene has been identified and
is referred to as allele C. This allele has a 39% to 50% or
higher frequency in AEA, 26% in ATA, and 25% in normal
individuals. Allele C is formed by the transversion of
adenine to cytosine, 444 bases from the translation start.
Semiquantitative studies by Sanak and colleagues of LTC4
synthase transcripts in peripheral blood eosinophils
showed increased numbers of mRNA copies in individuals
with AEA.
64 The increased transcripts correlated with the
allelic C variant.
The nature of this interaction has yet to be fully
elucidated. Of note, the transient increase in urinary LTE4
in AEA following oral aspirin provocation has been
observed only in allele C variants.
64 A Japanese study also




The age at onset of 300 subjects with AEA in the United
States was, on average, 34 years. In women, the age at onset
is usually earlier than in men, and severity is usually
classified in the moderate to severe persistent category.
Presentation in one European study showed a character-
istic sequence of symptoms, first beginning with persistent
rhinitis at around age 30 years of age and followed by
asthma, aspirin sensitivity, and then nasal polyposis. Atopy
was reported in one-third of cases.
66
Rhinorrhea and nasal congestion are usually the first
symptoms of AEA and are commonly refractory to
pharmacologic therapy. It becomes perennial and more
difficult to treat and then becomes associated with
anosmia, recurrent and chronic sinusitis, and nasal
polyposis.
5,6,66,67
After the ingestion of aspirin or other COX-1
inhibitors, bronchospasm occurs within 1 to 3 hours.
Care must be taken to differentiate selective COX-2
inhibitors from preferentially selective COX-2 inhibitors
such as rofecoxib, meloxicam, and ibuprofen.
Preferentially selective COX-2 inhibitors are selective
for COX-2 at low doses but at higher doses also inhibit
COX-1.
68–70 However, despite their overall safety profile,
caution must be used with these medications as several
cases have been described in which bronchospasm
occurred with their use.
71 Bronchospasm with COX-1
challenge can be accompanied by profuse rhinorrhea,
conjunctival injection, a scarlet flushing of the head and
neck, periorbital edema, abdominal pain, and even
urticaria.
5,6
A refractory period to the administration of aspirin or
other COX-1 inhibitors develops after sufficient quantities
of one or another of these medications is given to an AEA




AEA should be suspected when the following exists:
1. A history of exacerbation of asthma after ingestion of
aspirin or other non-NSAIDs
2. Chronic and intractable nasal congestion and watery
rhinorrhea, especially if specific IgE tests are negative
3. Nasal polyposis
4. Total or near-total opacification of the sinus cavities as
demonstrated by computed tomography
5. An individual with the rapid onset of a severe attack of
asthma with no previous insult who necessitates acute
emergency care, intensive care unit admission, or
endotracheal intubation
2,5,6
The oral challenge, beginning with small amounts of
aspirin and increasing the dose, is commonly used to
confirm the diagnosis. Threshold doses of 30 to 150 mg
(averaging 60–75 mg) evoke positive reactions and are the
most sensitive diagnostic tool. Inhaled bronchial chal-
lenged with acetylsalicylic acid–lysine is also used to
detect this syndrome. So, too, is nasal provocation with
aspirin-lysine, but this technique is much less sensitive
than bronchial challenge. Urinary LTE4 can also be
measured following aspirin challenge as an adjunctive
measure to confirm a positive bronchial challenge.
75
Preferably, aspirin challenge tests should be preceded by a
‘‘placebo challenge’’ to exclude the variability of bron-
chial responsiveness; however, as with any study, double-
blinded control studies are ideal.
2,5,6,66 Stevenson and
colleagues also reported that intranasal ketorolac admin-




AEA subjects should avoid all aspirin-containing com-
pounds and other analgesics that have the potential to
inhibit the COX-1 enzyme. They can safely ingest sodium
salicylate, salicylamide, choline magnesium trisalicylate,
Aspirin-Exacerbated Asthma 79benzydamine, chloroquine, azapropazone, and dextropro-
poxyphene. However, these drugs are poor analgesics and
have little anti-inflammatory effect.
77 Most individuals can
ingest acetaminophen, which primarily inhibits COX-3
while weakly inhibiting COX-1 and COX-2. However, in
some subjects, very sensitive to low provoking doses of
aspirin, acetaminophen-induced asthma is more common.
It can cause bronchoconstriction at doses greater than
1,000 mg in 34% of individuals with this syndrome.
78
Treatment
The guidelines used to treat and manage AEA are no
different from those used to treat moderate to severe
persistent ATA asthma. Individuals with AEA occasionally
require systemic corticosteroids in addition to their regular
maintenance therapy.
Leukotriene inhibitors, such as zileuton, which inhibits
5-LO, and leukotriene receptor antagonists, such as
montelukast and zafirlukast, are used to treat AEA.
However, ATA and AEA subjects on leukotriene inhibitors
have similar clinical outcomes, and urinary LTE4 cannot
be used to determine responses to these medications.
79,80
AEA subjects with the C allele appear to have a better
response with leukotriene receptor antagonists.
81
SurgeryfornasalpolyposisassociatedwithAEAresultsin
an 80% subjective improvement rate with a 40% chance or
more of recurrence of nasal polyps and persistence of nasal
symptoms. Thus, following sinus surgery, treatment with
topical and systemic corticosteroids, aspirin desensitization,
and leukotriene inhibitors is recommended.
88,89 Mild to
marked improvement in quality of life was reported in
individuals with AEA following sinus surgery in a Japanese
study.
82 McFadden and colleagues also reported improve-
ments in quality of life and pulmonary function tests (PFTs)
and a reduction in systemic and topical corticosteroid
requirements.
83 Simple polypectomy alone does not seem to
be as useful as endoscopic surgery owing to the excessive
amount of polypoid tissue burden in AEA.
2,84,85
Aspirin Desensitization
Desensitization became possible because of the discovery
of the refractory period in AEA.
30,72 Stevenson and
colleagues, in 1980, reported on two individuals with
AEA who were successfully desensitized to aspirin.
86 They
were continuously treated with daily aspirin, and both
individuals reported improvement in nasal patency, with
one regaining her sense of smell. Therapy with aspirin was
continued for months, with persistent nasal airway patency
and a diminished growth in nasal polyps, with an overall
reduction of half in the use of systemic corticosteroids and
improvement in rhinitis and asthma.
In another study by the same investigators, published
in 2003, of 172 subjects, 67% experienced a reduction in
their nasal airway symptoms and systemic and corticoster-
oid requirements as long as they maintained their daily
intake of aspirin. In 126 subjects who completed a year or
more of such treatment, 87% experienced good or
excellent improvement in sense of smell and general
assessment of nasal-sinus and asthma symptoms. This
study suggests that aspirin desensitization be used for
those who do not respond to topical glucocorticoids or
oral leukotriene antagonists. Those ideal for desensitiza-
tion have nasal polyposis, necessitating treatment with
systemic corticosteroids.
86,87
Sousa and colleagues reported that desensitization is
associated with a reduction in the number of inflammatory
cells in the nasal mucosa expressing the Cys-LT1 receptor
and that downregulation of receptor expression after
aspirin desensitization is the likely mechanism of action.
88
Pretreatment with Cys-LT receptor antagonists prior to
aspirin desensitization significantly decreases the risk of
AEA.
89,90
Other new modalities are under investigation, some
involving high-dose aspirin therapy for emergent desensi-
tization using oral protocols based on rapidly escalating
doses of aspirin. In individuals with aspirin-induced
urticaria-angioedema, a separate clinical entity with
perhaps similar pathogenic mechanisms, Wong and
colleagues reported the safe, rapid oral challenge desensi-
tization to aspirin.
91 In this study, aspirin administration
permitted individuals with coronary artery disease to
receive aspirin. Some other promising treatments, such as
tacrolimus, have proven ineffective.
92
Conclusion
AEA is perhaps the most well-defined asthma phenotype
compared with other asthma phenotypes, such as allergic,
non-allergic, exercise-induced, and infectious asthma. It is
a relatively common phenotype of asthma, affecting
primarily adults but also children with physician-
diagnosed asthma and, in some cases, subjects with no
previous history of asthma. It is often unrecognized and
underdiagnosed.
Subjects with moderate to severe asthma who have
severe nasal congestion, nasal polyposis, and radiologic
evidence of opacification of sinuses and who require
emergent care and/or intubation should be suspected to
80 Allergy, Asthma, and Clinical Immunology, Volume 4, Number 2, 2008have this form of asthma. A history of exacerbation
associated with the ingestion of aspirin or other COX-1
NSAIDs can be diagnostic for the phenotype. A refractory
period following aspirin challenge during which no
additional symptoms occur with additional aspirin or
other COX-1 NSAIDs may last up to 2 to 4 days.
PGE2 acts as a brake on LTC4 synthase, which
moderates the production of Cys-LTs. Individuals with
AEA have decreased levels of PGE2, which, in turn, causes
an overproduction of Cys-LTs, which theoretically causes
AEA. Genetic mechanism studies suggest that there is a
familial incidence; however, the exact mode of inheritance
is unknown.
Treatment of AEA primarily involves use of systemic
and inhaled glucocorticosteroids, short- and long-acting
b-agonists, leukotriene-modifying agents, and medical and
sometimes surgical treatment of the rhinitis and/or nasal
polyposis.
Leukotriene-modifying agents and inhaled corticoster-
oids, often in high doses, are the mainstay of therapy.
Aspirin desensitization is also a useful tool and in up to 60
to 70% of these patients, and the response sometimes can
be dramatic in reducing the overall dependence on inhaled
and/or systemic glucocorticosteroids.
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